ClinicalTrials.gov
Cure8 trial brief
A Study of SL-325 in Crohn's Disease Patients
Research and clinical trials
Abscess
Stricture
Fistula
Toxic Megacolon
Phase 2 clinical trial
Adult patients
Clinicians
Why This Matters
A new Phase 2 trial is testing SL-325 given IV for moderate-to-severe Crohn's disease with endoscopic response as the primary outcome. The study targets people who have not responded to or cannot tolerate several approved IBD therapies, so it could offer another option if later proven safe and effective.
Who Should Pay Attention
Adults with moderate-to-severe Crohn's disease (including those with prior biologic or JAK treatment failure), IBD clinicians, and researchers following new drug trials.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment232 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
The trial (not yet recruiting) plans to enroll about 232 adults and includes induction, maintenance, and long-term extension periods. The primary endpoint is endoscopic response at 12 weeks defined as ≥50% decrease in SES-CD.
Key inclusion and exclusion criteria focus on endoscopically confirmed moderate-to-severe ileal/colonic disease and prior treatment failures; important exclusions include active abscess, symptomatic strictures not passable by colonoscopy, certain prior surgeries, active TB, and prior exposure to anti-DR3/anti-TL1A agents.
Keep In Mind
This is a trial-record summary from ClinicalTrials.gov (not yet recruiting) and does not provide efficacy or safety results. SL-325 is described in the registry as an investigational IV agent; the record excludes participants with active TB, certain surgical histories, or specific complications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorShattuck Labs, Inc.
Trial IDNCT07753850
Study typeInterventional
Trial phasePhase 2
Enrollment232 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 12, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Artificial Intelligence-Based Classification and Prognostic Prediction in Small Bowel Crohn's Disease
AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...
Prominence of microbiota to predict fibrous stenosis in Crohn's diseas - Dove Medical Press
Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...
Agomab reports positive interim data in Crohn's disease trial - The Pharma Letter
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...